Performance analysis of CytomX Therapeutics (CTMX)
Annual Return
Over the past 3 years, CTMX has had an average annual return of +24.12%, outperforming the benchmark SPY, which returned +19.63% annual.
Over the past 5 years, CTMX has had an average annual return of -9.49%, underperforming the benchmark SPY, which returned +12.73% annual.
Over the past 10 years, CTMX has had an average annual return of -10.62%, underperforming the benchmark SPY, which returned +15.04% annual.
Since Oct 8, 2015, CTMX has had an average annual return of -11.58%, underperforming the benchmark SPY, which returned +14.82% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -19.72% | +313.78% | -33.61% | -3.06% | -63.06% | -33.89% | -21.17% | -44.96% | -28.47% | +92.09% | -47.34% | +61.78% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +33.59% | -5.62% | -12.49% | -10.21% | -14.67% | +4.16% | -8.81% | -19.72% | |||||
| 2025 | -17.42% | -20.33% | -6.10% | +17.04% | +255.98% | -14.31% | -3.52% | -6.89% | +56.42% | +11.89% | +19.91% | -0.48% | +313.78% |
| 2024 | -1.33% | +60.12% | -11.01% | -25.21% | +4.27% | -28.22% | +13.11% | -14.49% | +0% | -15.63% | +6.48% | -2.92% | -33.61% |
| 2023 | +68.79% | -20.35% | -29.75% | +7.94% | +4.91% | +0.53% | +1.20% | -13.79% | -14.02% | -14.70% | +26.38% | +11.50% | -3.06% |
| 2022 | +6.23% | -16.74% | -30.28% | -35.94% | -5.88% | +13.70% | -21.85% | +4.87% | -3.35% | -9.61% | +32.78% | -8.08% | -63.06% |
| 2021 | +5.49% | +13.59% | -1.53% | +21.09% | -23.51% | -11.59% | -14.53% | -5.36% | -0.58% | +16.50% | +11.46% | -34.48% | -33.89% |
| 2020 | -10.71% | -9.84% | +14.65% | +34.54% | -14.15% | -5.98% | -15.84% | +4.14% | -8.91% | -0.45% | +13.58% | -12.88% | -21.17% |
| 2019 | +12.46% | -33.92% | -4.20% | -11.53% | +1.57% | +16.16% | -8.12% | -14.84% | -15.94% | -16.94% | +2.13% | +32.74% | -44.96% |
| 2018 | +26.72% | +11.07% | -4.24% | -7.55% | -2.40% | -10.95% | +15.22% | -14.62% | -17.74% | -22.92% | -3.22% | +9.41% | -28.47% |
| 2017 | +5.74% | +7.57% | +38.16% | -9.04% | -10.31% | +10.02% | -12.97% | +28.10% | +5.15% | +10.07% | +3.50% | +1.98% | +92.09% |
Drawdown analysis of CytomX Therapeutics (CTMX)
The maximum drawdown for the CTMX was -98.74%, occurring on Apr 7, 2025. This drawdown has not yet recovered.
The current CTMX drawdown is -90.01%.
Since Oct 8, 2015 CTMX has experienced the following drawdowns:
- 50% or more: 2 times
- 40% or more: 2 times
- 30% or more: 2 times
- 20% or more: 3 times
- 10% or more: 3 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.74% | Mar 12, 2018 | 1778 | Apr 7, 2025 | Ongoing | Ongoing | Ongoing |
| -60.90% | Dec 4, 2015 | 134 | Jun 17, 2016 | 391 | Jan 5, 2018 | 525 |
| -29.87% | Oct 14, 2015 | 6 | Oct 22, 2015 | 18 | Nov 17, 2015 | 24 |
| -4.42% | Oct 8, 2015 | 3 | Oct 13, 2015 | 1 | Oct 14, 2015 | 4 |
| -4.11% | Mar 7, 2018 | 1 | Mar 8, 2018 | 1 | Mar 9, 2018 | 2 |
| -3.64% | Feb 7, 2018 | 1 | Feb 8, 2018 | 4 | Feb 14, 2018 | 5 |
| -2.80% | Jan 29, 2018 | 5 | Feb 5, 2018 | 1 | Feb 6, 2018 | 6 |
| -2.59% | Mar 2, 2018 | 2 | Mar 6, 2018 | 1 | Mar 7, 2018 | 3 |
| -2.50% | Nov 19, 2015 | 1 | Nov 20, 2015 | 1 | Nov 23, 2015 | 2 |
| -2.17% | Jan 22, 2018 | 4 | Jan 26, 2018 | 1 | Jan 29, 2018 | 5 |
| -2.13% | Jan 5, 2018 | 1 | Jan 8, 2018 | 1 | Jan 9, 2018 | 2 |
| -1.95% | Dec 2, 2015 | 1 | Dec 3, 2015 | 1 | Dec 4, 2015 | 2 |
| -1.35% | Jan 12, 2018 | 1 | Jan 16, 2018 | 1 | Jan 17, 2018 | 2 |
| -0.89% | Feb 14, 2018 | 1 | Feb 15, 2018 | 4 | Feb 22, 2018 | 5 |
| -0.39% | Jan 17, 2018 | 2 | Jan 19, 2018 | 1 | Jan 22, 2018 | 3 |